By Fineline Cube 
China’s Shanghai Ark Biopharmaceutical Co., Ltd. has entered into a new cooperation agreement with Germany-based Partex, an artificial intelligence (AI)-empowered drug developer. Building on their initial partnership focused on the autotaxin inhibitor AK0707, the companies will now jointly develop and license out the ATR inhibitor AK0658.
Collaboration Details
Under the agreement, Ark Bio will lead the preclinical development and early clinical strategy for AK0658. Partex will utilize its independently developed Asset42 AI platform to explore the drug’s full lifecycle management potential across multiple new indications. Partex will also spearhead the selection of strategic partners and global licensing efforts.
ATR Inhibitor AK0658
AK0658 is a preclinical ATR inhibitor targeting cancers with abnormal DNA damage repair (DDR) pathways. The collaboration aims to accelerate its development and commercialization, leveraging Partex’s AI capabilities to identify optimal therapeutic applications and enhance the drug’s market potential.-Fineline Info & Tech